Estefania Labanca, PhD
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
About Estefania Labanca
Present Title & Affiliation
Primary Appointment
Instructor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2019 | MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences (GSBS), Houston, Texas, US, Cancer Biology, Ph.D |
| 2014 | Universidad de Buenos Aires, Buenos Aires, AR, Molecular Biology, BS/MS |
Postgraduate Training
| 2020-2023 | Research Fellowship, The University of Texas MD Anderson Cancer Center, Houston, Texas |
Experience & Service
Academic Appointments
Instructor, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - 2023
Associate Member Faculty, MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences (GSBS), Houston, TX, 2023 - 2023
Honors & Awards
| Undergraduate fellowship to promote Scientific Vocations, National Interuniversity Council, Secretariat of Science and Technology, University of Buenos Aires | |
| Trainee Research Day Poster Competition Finalist in Translational Research, MD Anderson Cancer Center | |
| Floyd Haar, MD Endowed Memorial Scholarship in Memory of Freda Haar, Graduate School of Biomedical Sciences | |
| Travel Award, Graduate School of Biomedical Sciences | |
| Takeda Oncology Scholar-in-Training Award, American Association for Cancer Research | |
| T.C. Hsu Memorial Scholarship, Graduate School of Biomedical Sciences | |
| Lightning talk poster presentation winner, 2nd Annual Meeting, NCI Patient-Derived Models of Cancer | |
| Rolanette and Berdon Lawrence Research Award finalist, Bone Disease Program of Texas | |
| Society for Basic Urologic Research/Society of Women in Urology Award, in honor of Dr. Nora Navone, Society for Basic Urologic Research/Society of Women in Urology | |
| Endowed Fellowship Pilot Project Grant Award, Office of Research Education and Training, MD Anderson Wllm Pippin Jr Fellow GU Rsch and TH & MP Scott Fellow Cncr Rsch Endowed Fellowships | |
| Rising Stars and Emerging Leaders, 40 Under 40 in Cancer | |
| PCF Young Investigator Award, Prostate Cancer Foundation (PCF) 2024 |
Selected Publications
Peer-Reviewed Articles
- Toro A, Arevalo AP, Pereira-Gomez M, Sabater A, Zizzi EA, Perbolianachis P, Pascual G, Lage-Vickers S, Porfido JL, Achinelli I, Seniuk R, Bizzotto J, Sanchis P, Olivera A, Leyva A, Moreno P, Costabile A, Fajardo A, Carrion F, Flo M, Olivero-Deibe N, Rodriguez F, Nin N, Anselmino N, Labanca E, Vazquez E, Cotignola J, Alonso DF, Valacco MP, Marti M, Gentile F, Cherkasov A, Crispo M, Moratorio G, Gueron G. Blood matters: the hematological signatures of Coronavirus infection. Cell Death Dis 15(11):863, 2024. e-Pub 2024. PMID: 39609423.
- Pascual G, Sabater A, Bizzotto J, Seniuk R, Sanchis P, Ledesma-Bazan S, Labanca E, Scorticati C, Mazza O, Vazquez E, Toro A, Prada F, Gueron G, Cotignola J. AR (CAG)(n) Microsatellite and APEX1 c.444T>G (p.Asp148Glu) Polymorphisms as Independent Prognostic Biomarkers in Prostate Cancer: Insights from an Argentinian Cohort. Cancers (Basel) 16(22), 2024. e-Pub 2024. PMID: 39594771.
- Sabater A, Sanchis P, Seniuk R, Pascual G, Anselmino N, Alonso DF, Cayol F, Vazquez E, Marti M, Cotignola J, Toro A, Labanca E, Bizzotto J, Gueron G. Unmasking Neuroendocrine Prostate Cancer with a Machine Learning-Driven Seven-Gene Stemness Signature That Predicts Progression. Int J Mol Sci 25(21), 2024. e-Pub 2024. PMID: 39518911.
- Tien JC, Luo J, Chang Y, Zhang Y, Cheng Y, Wang X, Yang J, Mannan R, Mahapatra S, Shah P, Wang XM, Todd AJ, Eyunni S, Cheng C, Rebernick RJ, Xiao L, Bao Y, Neiswender J, Brough R, Pettitt SJ, Cao X, Miner SJ, Zhou L, Wu YM, Labanca E, Wang Y, Parolia A, Cieslik M, Robinson DR, Wang Z, Feng FY, Chou J, Lord CJ, Ding K, Chinnaiyan AM. CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13. Cell Rep Med 5(10):101758, 2024. e-Pub 2024. PMID: 39368479.
- Sabater A, Sanchis P, Seniuk R, Pascual G, Anselmino N, Alonso D, Cayol F, Vazquez E, Marti M, Cotignola J, Toro A, Labanca E, Bizzotto J, Gueron G. Unmasking Neuroendocrine Prostate Cancer with a Machine Learning-Driven 7-Gene Stemness Signature that Predicts Progression. medRxiv None(None):None, 2024. e-Pub 2024. PMID: 39399052.
- Archer M, Begemann D, Gonzalez-Kozlova E, Nepali PR, Labanca E, Shepherd P, Dogra N, Navone N, Kyprianou N. Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer. Mol Cancer Res None(None):None, 2024. e-Pub 2024. PMID: 38648082.
- Anselmino N, Labanca E, Shepherd PDA, Dong J, Yang J, Song X, Nandakumar S, Kundra R, Lee C, Schultz N, Zhang J, Araujo JC, Aparicio AM, Subudhi SK, Corn PG, Pisters LL, Ward JF, Davis JW, Vazquez ES, Gueron G, Logothetis CJ, Futreal A, Troncoso P, Chen Y, Navone NM. Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series. Clin Cancer Res 30(10):2272-2285, 2024. e-Pub 2024. PMID: 38488813.
- Tien JC, Chang Y, Zhang Y, Chou J, Cheng Y, Wang X, Yang J, Mannan R, Shah P, Wang XM, Todd AJ, Eyunni S, Cheng C, Rebernick RJ, Xiao L, Bao Y, Neiswender J, Brough R, Pettitt SJ, Cao X, Miner SJ, Zhou L, Wu YM, Labanca E, Wang Y, Parolia A, Cieslik M, Robinson DR, Wang Z, Feng FY, Lord CJ, Ding K, Chinnaiyan AM. CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality. bioRxiv, 2024. e-Pub 2024. PMID: 38562774.
- Toro A, Lage-Vickers S, Bizzotto J, Vilicich F, Sabater A, Pascual G, Ledesma-Bazan S, Sanchis P, Ruiz MS, Arevalo AP, Porfido JL, Abbate M, Seniuk R, Labanca E, Anselmino N, Navone NM, Alonso DF, Vazquez E, Crispo M, Cotignola J, Gueron G. Pin-Pointing the Key Hubs in the IFN-γ Pathway Responding to SARS-CoV-2 Infection. Viruses 14(10), 2022. e-Pub 2022. PMID: 36298734.
- Sanchis P, Anselmino N, Lage-Vickers S, Sabater A, Lavignolle R, Labanca E, Shepherd PDA, Bizzotto J, Toro A, Mitrofanova A, Valacco MP, Navone N, Vazquez E, Cotignola J, Gueron G. Bone Progenitors Pull the Strings on the Early Metabolic Rewiring Occurring in Prostate Cancer Cells. Cancers (Basel) 14(9), 2022. e-Pub 2022. PMID: 35565211.
- Labanca E, Yang J, Shepherd PDA, Wan X, Starbuck MW, Guerra LD, Anselmino N, Bizzotto JA, Dong J, Chinnaiyan AM, Ravoori MK, Kundra V, Broom BM, Corn PG, Troncoso P, Gueron G, Logothethis CJ, Navone NM. Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer. Eur Urol Oncol 5(2):164-175, 2022. e-Pub 2022. PMID: 34774481.
- Lage-Vickers S, Sanchis P, Bizzotto J, Toro A, Sabater A, Lavignolle R, Anselmino N, Labanca E, Paez A, Navone N, Valacco MP, Cotignola J, Vazquez E, Gueron G. Exploiting Interdata Relationships in Prostate Cancer Proteomes: Clinical Significance of HO-1 Interactors. Antioxidants (Basel) 11(2), 2022. e-Pub 2022. PMID: 35204174.
- Labanca E, Bizzotto J, Sanchis P, Anselmino N, Yang J, Shepherd PDA, Paez A, Antico-Arciuch V, Lage-Vickers S, Hoang AG, Tang X, Raso MG, Titus M, Efstathiou E, Cotignola J, Araujo J, Logothetis C, Vazquez E, Navone N, Gueron G. Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel. Oncogene 40(44):6284-6298, 2021. e-Pub 2021. PMID: 34584218.
- Cascardo F, Anselmino N, Páez A, Labanca E, Sanchis P, Antico-Arciuch V, Navone N, Gueron G, Vázquez E, Cotignola J. HO-1 Modulates Aerobic Glycolysis through LDH in Prostate Cancer Cells. Antioxidants (Basel) 10(6), 2021. e-Pub 2021. PMID: 34208670.
- Lage-Vickers S, Bizzotto J, Valacco MP, Sanchis P, Nemirovsky S, Labanca E, Scorticati C, Mazza O, Mitrofanova A, Navone N, Vazquez E, Cotignola J, Gueron G. The expression of YWHAZ and NDRG1 predicts aggressive outcome in human prostate cancer. Commun Biol 4(1):103, 2021. e-Pub 2021. PMID: 33483585.
- Palanisamy N, Yang J, Shepherd PDA, Li-Ning-Tapia EM, Labanca E, Manyam GC, Ravoori MK, Kundra V, Araujo JC, Efstathiou E, Pisters LL, Wan X, Wang X, Vazquez ES, Aparicio AM, Carskadon SL, Tomlins SA, Kunju LP, Chinnaiyan AM, Broom BM, Logothetis CJ, Troncoso P, Navone NM. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. Clin Cancer Res 26(18):4933-4946, 2020. e-Pub 2020. PMID: 32576626.
- Ortiz E, Sanchis P, Bizzotto J, Lage-Vickers S, Labanca E, Navone N, Cotignola J, Vazquez E, Gueron G. Myxovirus Resistance Protein 1 (MX1), a Novel HO-1 Interactor, Tilts the Balance of Endoplasmic Reticulum Stress towards Pro-Death Events in Prostate Cancer. Biomolecules 10(7), 2020. e-Pub 2020. PMID: 32640729.
- Anselmino N, Starbuck M, Labanca E, Cotignola J, Navone N, Gueron G, Zenclussen AC, Vazquez E. Heme Oxygenase-1 Is a Pivotal Modulator of Bone Turnover and Remodeling: Molecular Implications for Prostate Cancer Bone Metastasis. Antioxid Redox Signal 32(17):1243-1258, 2020. e-Pub 2020. PMID: 31861963.
- Anselmino N, Bizzotto J, Sanchis P, Lage-Vickers S, Ortiz E, Valacco P, Paez A, Labanca E, Meiss R, Navone N, Cotignola J, Vazquez E, Gueron G. HO-1 Interactors Involved in the Colonization of the Bone Niche: Role of ANXA2 in Prostate Cancer Progression. Biomolecules 10(3), 2020. e-Pub 2020. PMID: 32197509.
- Gueron G, Anselmino N, Chiarella P, Ortiz EG, Lage Vickers S, Paez AV, Giudice J, Contin MD, Leonardi D, Jaworski F, Manzano V, Strazza A, Montagna DR, Labanca E, Cotignola J, D Accorso N, Woloszynska-Read A, Navone N, Meiss RP, Ruggiero R, Vazquez E. Game-changing restraint of Ros-damaged phenylalanine, upon tumor metastasis. Cell Death Dis 9(2):140, 2018. e-Pub 2018. PMID: 29396431.
- Paez AV, Pallavicini C, Schuster F, Valacco MP, Giudice J, Ortiz EG, Anselmino N, Labanca E, Binaghi M, Salierno M, Martí MA, Cotignola JH, Woloszynska-Read A, Bruno L, Levi V, Navone N, Vazquez ES, Gueron G. Heme oxygenase-1 in the forefront of a multi-molecular network that governs cell-cell contacts and filopodia-induced zippering in prostate cancer. Cell Death Dis 7(12):e2570, 2016. e-Pub 2016. PMID: 28032857.
- Labanca E, De Luca P, Gueron G, Paez A, Moiola CP, Massillo C, Porretti J, Giudice J, Zalazar F, Navone N, Vazquez E, De Siervi A. Association of HO-1 and BRCA1 Is Critical for the Maintenance of Cellular Homeostasis in Prostate Cancer. Mol Cancer Res 13(11):1455-64, 2015. e-Pub 2015. PMID: 26227317.
Other Articles
- Habowski AN, Budagavi DP, Scherer SD, Aurora AB, Caligiuri G, Flynn WF, Langer EM, Brody JR, Sears RC, Foggetti G, Arnal Estape A, Nguyen DX, Politi KA, Shen X, Hsu DS, Peehl DM, Kurhanewicz J, Sriram R, Suarez M, Xiao S, Du Y, Li XN, Navone NM, Labanca E, Willey CD Patient-Derived Models of Cancer in the NCI PDMC Consortium: Selection, Pitfalls, and Practical Recommendations. Cancers (Basel) 16(3), 2024. PMID: 38339316.
- Labanca E, Vazquez ES, Corn PG, Roberts JM, Wang F, Logothetis CJ, Navone NM Fibroblast growth factors signaling in bone metastasis. Endocr Relat Cancer 27(7):R255-R265, 2020. PMID: 32369771.
Book Chapters
- Navone NM, Labanca E. Modeling Cancer Metastasis. In: Patient Derived Xenograft Models of Human Cancer. None. Springer International Publishing AG 2017. Humana Press, Ch7. p 93-114, 2017.
Selected Presentations & Talks
Local Presentations
- 2024. Challenges in Prostate Cancer Modeling: Potential of PDX-derived Organoids as a Complementary Tool for Research. Invited. Spatial Biology Seminar. Houston, TX, US.
- 2024. Advancing Prostate Cancer Research: The MDA PCa PDX Program. Invited. URO Today. Houston, Texas, US.
- 2023. Uncovering bone tropic and colonization programs driven by FGFR1 via Wnt-stemness in prostate cancer metastasis. Conference. Bone Disease Program of Texas Scientific Retreat. Houston, TX, US.
- 2018. Fibroblast growth factor receptors in prostate cancer bone metastases. Conference. Bone Disease Program of Texas Scientific Retreat. Houston, TX, US.
- 2018. Fibroblast growth factor receptors in prostate cancer bone metastases. Conference. GSBS Student Research Day – MD Anderson Cancer Center. Houston, TX, US.
- 2018. A specific pan-FGFR inhibitor has antitumor activity against prostate cancer patient derived xenografts, PDX, expressing high FGFR1. Conference. Bone Disease Program of Texas Scientific Retreat. Houston, TX, US.
- 2017. Fibroblast growth factor receptors in prostate cancer bone metastases. Conference. Cancer Biology Program Retreat 2017. Galveston, TX, US.
- 2017. Fibroblast growth factor receptors in prostate cancer bone metastases. Conference. MD Anderson. Houston, TX, US.
- 2017. Fibroblast growth factor receptors in prostate cancer bone metastases. Conference. Bone Disease Program of Texas Scientific Retreat. Houston, TX, US.
- 2016. Different responses triggered by isoforms of Fibroblast growth factor receptor 1 in prostate cancer cells. Conference. GSBS Student Research Day – MD Anderson Cancer Center. Houston, TX, US.
- 2015. Alpha and beta isoforms of fibroblast growth factor receptor 1 trigger different responses in prostate cancer cells. Conference. Trainee Research Day – MD Anderson Cancer Center. Houston, TX, US.
National Presentations
- 2024. Disruption of bone-tumor interplay in metastatic prostate cancer. Poster. Scottsdale, AR, US.
- 2024. From Tumor Suppression to Bone Remodeling: The Dual Role of Ra-223 in Advanced Prostate Cancer. Poster. Carlsbad, CA, US.
- 2024. Defining FGFR-Driven Progression in Prostate Cancer Bone Metastases to Leverage Treatment Outcomes. Invited. Gordon Research Conference. Galveston, TX, US.
- 2023. Impact of Wnt pathway on androgen receptor inhibition treatment in Prostate Cancer. Conference. 30th Annual Prostate Cancer Foundation Scientific Retreat. Carlsbad, CA, US.
- 2023. Unraveling the metabolic rewiring in prostate cancer progression. Conference. 30th Annual Prostate Cancer Foundation Scientific Retreat. Carlsbad, CA, US.
- 2023. Delineating FGFR-progression mechanisms via Wnt-stemness in metastatic prostate cancer. Conference. 30th Annual Prostate Cancer Foundation Scientific Retreat. Carlsbad, CA, US.
- 2023. Building on Insights from Murine Models and Clinical Studies of Prostate Cancer Bone Metastases. Invited. 30th Annual Prostate Cancer Foundation Scientific Retreat. Carlsbad, CA, US.
- 2023. Lipid Metabolism and PKA: Therapeutic Targets in Prostate Cancer Bone Metastasis. Conference. 30th Annual Prostate Cancer Foundation Scientific Retreat. Carlsbad, CA, US.
- 2023. HO-1 regulates prostate cancer progression by modulating stemness and metastasis genes. Conference. 30th Annual Prostate Cancer Foundation Scientific Retreat. Carlsbad, CA, US.
- 2022. Role of WNT Canonical Pathway in Prostate Cancer Progression. Virtual. Invited. 4th Annual Meeting of Patient-Derived Models of Cancer-NCI. Virtual, US.
- 2022. It's all about communication: metabolic rewiring of prostate cancer cells in the bone niche. Conference. The Prostate Cancer Foundation 29th Annual Scientific Retreat 2022. Carlsbad, CA, US.
- 2022. Early metabolic rewiring of prostate cancer cells triggered by bone progenitors defines survival of metastatic prostate cancer. Conference. American Association for Cancer Research Annual Meeting. New Orleans, LA, US.
- 2021. Impact of WNT canonical activating mutations on androgen deprivation therapy response. Invited. 3rd Annual Meeting of Patient-Derived Models of Cancer-NCI. Virtual, US.
- 2021. Insights into cancer biology through an integrative genomic analysis of PCa PDXs. Invited. 3rd Annual Meeting of Patient-Derived Models of Cancer-NCI. Virtual, US.
- 2021. Prostate cancer bone metastases induced by FGFR1 signaling. Invited. Endocrinology and Diabetes 3rd Edition 2021. Virtual, US.
- 2021. Molecular signature predictive of FGFR blockade response: an essential tool for therapy development. Conference. The Prostate Cancer Foundation 28th Annual Scientific Retreat 2021, US.
- 2021. The Role of Wnt/Beta-Catenin in the Progression of Castration Resistance of Prostate Cancer in Bone. Conference. The Prostate Cancer Foundation 28th Annual Scientific Retreat 2021, US.
- 2021. Metastatic prostate cancer, a journey of metabolic rewiring triggered by bone cells. Conference. The Prostate Cancer Foundation 28th Annual Scientific Retreat 2021, US.
- 2021. Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel. Conference. AACR. Virtual, US.
- 2021. Androgen-deprivation therapy boosts MX1 expression, a silent effector against COVID-19. Conference. AACR. Virtual, US.
- 2021. ADT poses a therapeutic advantage against COVID-19 by enhancing the activation of the human myxovirus resistance gene 1 (MX1). Conference. Society for Basic Urologic Research Annual Meeting, US.
- 2021. Landing and homing in the bone niche, a milestone associated with metabolic rewiring of prostate tumor cells triggered by bone precursors. Conference. Society for Basic Urologic Research Annual Meeting. Virtual, US.
- 2020. Patient-Derived Models of Prostate Cancer for Personalized Medicine. Invited. 2nd Annual Meeting of Patient-Derived Models of Cancer-NCI. Virtual, US.
- 2020. FGFR1 isoforms mediate progression of prostate cancer to bone metastases. Conference. 2nd Annual Meeting of Patient-Derived Models of Cancer-NCI. Virtual, US.
- 2020. Clinical implications of Wnt Canonical pathway in metastatic prostate cancer. Conference. 2nd Annual Meeting of Patient-Derived Models of Cancer-NCI. Virtual, US.
- 2020. Androgen-deprivation therapy boosts MX1 expression, a silent effector against COVID-19. Conference. The Prostate Cancer Foundation 27th Annual Scientific Retreat 2020. Virtual, US.
- 2020. Novel insights into developing FGFR blockade as a therapy for advanced prostate cancer. Conference. The Prostate Cancer Foundation 27th Annual Scientific Retreat 2020. Virtual, US.
- 2020. Ketone Bodies as the main metabolic fuel driving Castrate-Resistant Prostate Cancer. Conference. The Prostate Cancer Foundation 27th Annual Scientific Retreat 2020. Virtual, US.
- 2020. HO-1 interactors in prostate cancer: role of MX1 in pro-death endoplasmic reticulum stress. Conference. The Prostate Cancer Foundation 27th Annual Scientific Retreat 2020, US.
- 2020. Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer. Invited. Multi-Institutional Prostate Cancer Program Retreat - 13th Annual. Virtual, US.
- 2020. Tyrosine kinase inhibition of fibroblast growth factor receptor 1 in advanced prostate cancer. Conference. AACR. Virtual, US.
- 2019. Relevance of FGFR1 and its Isoforms in Prostate Cancer Bone Metastases. Invited. Bone Disease Program of Texas, T-Bone Trainee Seminar, US.
- . Conference. The Prostate Cancer Foundation 25th Annual Scientific Retreat 2018. Carlsbad, CA, US.
- 2018. FGFR1/FGFR1 isoforms accelerate prostate cancer progression to metastasis. Conference. The Prostate Cancer Foundation 25th Annual Scientific Retreat 2018. Carlsbad, CA, US.
- 2018. FGFR1/FGFR1 isoforms in prostate cancer progression to metastasis. Conference. Metastasis Research Society Biennial Congress. Princeton, NJ, US.
- 2018. A specific pan-FGFR inhibitor has antitumor activity against prostate cancer patient derived xenografts, PDX, expressing high FGFR1. Conference. American Association for Cancer Research Annual Meeting. Chicago, IL, US.
- 2017. Heme-oxygenase 1 drives the metabolic fate in prostate cancer. Conference. American Association for Cancer Research Special Conference: Prostate Cancer: Advances in Basic, Translational, and Clinical Research. Orlando, FL, US.
- 2017. Expression of fibroblast growth factor 1 isoforms and activation of different pathways in prostate cancer progression. Conference. American Association for Cancer Research Special Conference: Prostate Cancer: Advances in Basic, Translational, and Clinical Research. Orlando, FL, US.
- 2017. The Role of Activated Beta-catenin/Wnt Signaling in the Progression of Castration Resistant Prostate Cancer in Bone. Conference. American Association for Cancer Research Special Conference: Prostate Cancer: Advances in Basic, Translational, and Clinical Research. Orlando, FL, US.
- 2016. Heme Oxygenase -1 (HO-1) in the forefront of a multi-molecular network that governs cell-cell contacts and filopodia-induced zippering in prostate cancer. Conference. The Prostate Cancer Foundation 23rd Annual Scientific Retreat 2016. Carlsbad, CA, US.
- 2016. Clinical implications for m-tyrosine, an isomer of p-tyrosine, for the treatment of aggressive prostate Tumors. Conference. American Association for Cancer Research Annual Meeting. New Orleans, LA, US.
- 2016. Hitting the brakes on the migratory capacity of tumoral cells: Targeting key regulators of actin dynamics in prostate cancer. Conference. American Association for Cancer Research Annual Meeting. New Orleans, LA, US.
- 2016. Alpha and beta isoforms of fibroblast growth factor receptor 1 trigger different responses in prostate cancer cells. Conference. American Association for Cancer Research Annual Meeting. New Orleans, LA, US.
- 2016. Analyses of a prostate cancer patient-derived xenografts series, a resource for translational research. Conference. American Association for Cancer Research Special Conference. New Orleans, LA, US.
- 2015. Fibroblast growth factor receptor 1 isoforms in prostate cancer bone metastases. Conference. American Association for Cancer Research Annual Meeting. Philadelphia, PA, US.
- 2015. HO-1 modulates the actin stress fiber architecture in prostate cancer cells: towards a less aggressive phenotype. Conference. American Association for Cancer Research Annual Meeting. Philadelphia, PA, US.
- 2015. Heme-oxygenase 1 (HO-1) re-orchestrates prostate cancer cellular architecture towards a more epithelial-like morphology. Conference. Gordon Research Seminar: Directed Cell Migration. Galveston, TX, US.
- 2015. Heme-oxygenase 1 (HO-1) re-orchestrates prostate cancer cellular architecture towards a more epithelial-like morphology. Conference. Gordon Research Conference: Directed Cell Migration. Galveston, TX, US.
- 2014. CtBP1 is implicated in prostate tumor development in a metabolic syndrome-like disease in vivo model. Conference. American Association for Cancer Research Annual Meeting. San Diego, CA, US.
- 2013. Molecular link that associates high fat diet and prostate tumor growth. Conference. AACR. Washington, D.C, US.
- 2013. FGF signaling axis mediates the interaction between prostate cancer cells and osteoblasts, implication to PCa bone metastases. Conference. 8th Annual Undergraduate Student Caucus and Poster Competition, US.
- 2012. Heme oxygenase 1 (HO-1): An auspicious target for state-of-the-art anti-angiogenic therapeutic strategies and new insights in prostate carcinogenesis. Conference. AACR. Chicago, IL, US.
- 2011. HO-1 challenges the epithelial mesenchymal transition in prostate cancer. Conference. AACR. Orlando, FL, US.
International Presentations
- 2024. Multimodal metabolic imaging of resistance to anti-androgens in prostate cancer patient-derived xenografts. Conference, CA.
- 2023. Nuclear HO-1 interactors might define a neuroendocrine signature in prostate cancer. Conference. Argentinean Society of Clinic Investigation (SAIC) Scientific Annual Meeting. Mar del Plata, AR.
- 2023. Beyond the enzymatic function of HO-1 in prostate cancer. Conference. XXVI Argentine and International Clinical Oncology Conference. Mar del Plata, AR.
- 2023. PKA orchestrates the interaction between metastatic prostate cancer cells and the bone microenvironment. Conference. Argentinean Society of Clinic Investigation (SAIC) Scientific Annual Meeting. Mar del Plata, AR.
- 2023. PKA: a key player for the colonization of the bone niche by prostate cancer cells. Conference. European Association for Cancer Research Annual Congress. Torino, IT.
- 2022. The fa(s)t conquest of prostate cancer cells in the bone niche. Conference. European Association for Cancer Research Conference on Cancer Metabolism. Bilbao, ES.
- 2021. Ketone body metabolism promotes prostate cancer castrate resistant progression. Invited. Argentinean Society of Clinic Investigation (SAIC) Scientific Annual Meeting, AR.
- 2021. Antiandrogens pose a protective effect against covid-19 by boosting the human myxovirus resistance gene 1 (mx1). Invited. Argentinean Society of Clinic Investigation (SAIC) Scientific Annual Meeting, AR.
- 2021. Pinpointing the key players in metabolic rewiring of prostate tumor cells towards progression in the bone niche. Invited. Argentinean Society of Clinic Investigation (SAIC) Scientific Annual Meeting, AR.
- 2019. Heme oxygenase-1 (HO-1) modulates aerobic glycolysis through regulation of lactate dehydrogenase (LDH) in prostate cancer cells. Conference. Argentinean Society of Clinic Investigation (SAIC) LXIII Scientific Annual Meeting. Mar del Plata, AR.
- 2018. The oxidized aminoacid m-tyrosine re-shaped the metabolic fate of tumor cells impairing metastases . Conference. Argentinean Society of Clinic Investigation (SAIC) LXIII Scientific Annual Meeting. Mar del Plata, AR.
- 2017. Fibroblast growth factor receptors in prostate cancer bone metastases. Conference. 2nd Fibroblast Growth Factors in Development and Repair Conference- Fusion Conferences Limited. Cancun, MX.
- 2016. Heme oxygenase -1 (ho-1) in the forefront of a multi-molecular network that governs cell-cell contacts and filopodia-induced zippering in prostate cancer. Conference. Argentinean Society of Clinic Investigation (SAIC) LXI Scientific Annual Meeting. Mar del Plata, AR.
- 2013. Agents that generate DNA damage and/or oxidative stress regulate HO-1 transcription in Prostate Cancer. Conference. Argentinean Society of Clinic Investigation (SAIC) LVIII Scientific Annual Meeting. Mar del Plata, AR.
- 2012. BRCA1 induces HO-1 transcription in prostate cancer xenografts. Invited. Argentinean Society of Clinic Investigation (SAIC) LVII Scientific Annual Meeting. Mar del Plata, AR.
- 2012. BRCA1 protects cells against oxidative stress upregulating HO-1 transcription. Invited. 7th International Meeting on Heme Oxygenase & Related Enzymes. Edinburgh, GB.
- 2012. Unraveling the anti-angiogenic properties of HO-1 in prostate cancer. Invited. 7th International Meeting on Heme Oxygenase & Related Enzymes. Edinburgh, GB.
- 2011. A new function for BRCA1 in tumor suppression: the maintenance of cellular homeostasis through the transcriptional regulation of HO-1. Conference. Argentinean Society of Clinic Investigation (SAIC) LVI Scientific Annual Meeting. Mar del Plata, AR.
Formal Peers
- 2023. Metabolism working group. Invited. Prostate Cancer Foundation, US.
- 2022. Seminar Biological Chemistry Department. Invited. School of Sciences, University of Buenos Aires, Argentina, US.
- 2022. Tumorigenesis working group. Invited. Prostate Cancer Foundation, US.
- 2020. Cancer Biology Student Speaker Series. Invited. University of Texas MD Anderson Graduate School of Biomedical Sciences, US.
- 2019. Exchange of ideas on concepts, patient treatments, process, and economic approaches on the Medicine industry (Visit to MD Anderson Cancer Center). Invited. Argentine delegation of AmCham Argentina's US Health Care Mission v, US.
Grant & Contract Support
| Title: | Targeting Metabolic Rewiring to Inhibit Castration-Resistant Prostate Cancer Progression and Bone Metastasis |
| Funding Source: | Prostate Cancer Foundation Young Investigator Award |
| Role: | PI |
| Title: | Endowed Fellowship Pilot Grant |
| Funding Source: | William Pippin Jr Fellow GU Rsch & TH & MP Scott Fellow Cancer Research Fellowship |
| Role: | Principal Investigator-MDACC |
| Title: | Drugging the Enzymes of the Ketogenic Pathway for Castration-Resistant Prostate Cancer Therapy |
| Funding Source: | Scientific and Technologic Projects (PICT)/National Agency for the Promotion of Science and Technology (Mincyt) |
| Role: | Co-PI |
| Title: | Targeting B7-H3 in Aggressive Variant Prostate Cancer |
| Funding Source: | Prostate Cancer Foundation Challenge Award |
| Role: | Co-I |
| Title: | Identifying Different Metabolic Sub-types of Prostate Cancer for Early Therapeutic Assessment |
| Funding Source: | DOD |
| Role: | Co-I |
| Title: | Patient-Derived Models of Prostate Cancer for Personalized Medicine |
| Funding Source: | NIH/NCI |
| Role: | Instructor |
| Title: | CAR-T Cells Armored with Engineered Receptor Tyrosine Kinases for Prostate Cancer Treatment |
| Funding Source: | DOD/TAMU |
| Role: | Co-I |
| Title: | Development of CAR T Cells Integrated with Engineered FGF Receptors for Prostate Cancer Treatment |
| Funding Source: | NIH/Texas A&M University |
| Role: | Co-I |
| Title: | Understanding Tumorigenesis and Identifying Therapeutic Targets in CDK12-Mutant Prostate Cancer |
| Funding Source: | DOD/MSKCC |
| Role: | Co-I |
| Title: | Integrative Tissue "Omics" Strategies to Define Risk Stratification Biomarkers for Intermediate Gleason Scores in Prostate Cancer |
| Funding Source: | Scientific and Technologic Projects (PICT)/ National Agency for the Promotion of Science and Technology (Mincyt) |
| Role: | Co-I |
| Title: | Therapeutic Implications for the Metabolic Shift occurring in Castration Resistant Prostate Cancer |
| Funding Source: | Scientific and Technologic Projects (PICT)/ National Agency for the Promotion of Science and Technology (Mincyt) |
| Role: | Co-I |
Patient Reviews
CV information above last modified February 21, 2025